Uric acid-induced C-reactive protein expression: Implication on cell proliferation and nitric oxide production of human vascular cells

Journal of the American Society of Nephrology

Volumn 16, Issue 12, 2005, Pages 3553-3562

  Kang, Duk Hee ^a,e   Park, Sung Kwang ^b   Lee, In Kyu ^c   Johnson, Richard J ^d  

^a Ewha Womans University School of Medicine   (South Korea)

^b Chonbuk National University Medical School   (South Korea)

^c Kyungpook National University School of Medicine   (South Korea)

^d UNIVERSITY OF FLORIDA   (United States)

^e Ewha Womans University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANION TRANSPORT PROTEIN; C REACTIVE PROTEIN; EXTRACELLULAR SIGNAL REGULATED KINASE 44; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PROBENECID; UNCLASSIFIED DRUG; URIC ACID; RNA;

ARTICLE; ATHEROSCLEROSIS; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; HEART DISEASE; HUMAN; HUMAN CELL; HYPERTENSION; HYPERURICEMIA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; UMBILICAL VEIN; UPREGULATION; VASCULAR SMOOTH MUSCLE; ANALYSIS OF VARIANCE; BIOSYNTHESIS; CELL CULTURE; CELL MOTION; CYTOLOGY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; POLYMERASE CHAIN REACTION; PROBABILITY; SENSITIVITY AND SPECIFICITY; VASCULAR ENDOTHELIUM;

ANALYSIS OF VARIANCE; BASE SEQUENCE; C-REACTIVE PROTEIN; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; HUMANS; MOLECULAR SEQUENCE DATA; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; POLYMERASE CHAIN REACTION; PROBABILITY; RNA; SENSITIVITY AND SPECIFICITY; UMBILICAL VEINS; UP-REGULATION; URIC ACID;

EID: 33645461474     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2005050572     Document Type: Article

References (37)

1. Ridker PM: High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 103: 1813-1818, 2001
2. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347: 1557-1565, 2002
3. Jialal I, Devaraj S: Inflammation and atherosclerosis: The value of the high sensitive C-reactive protein assay as a marker. Am J Clin Pathol 116: S108-S115, 2001
4. Torzewski M, Rist C, Mortensen RF, Zwaka TP, Bienek M, Waltenberger J, Koenig W, Schmitz G, Hombach V, Torzewski J: C-reactive protein in the arterial intima: Role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 20: 2094-2099, 2000
5. Pasceri V, Willerson JT, Yeh ETH: Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102: 2165-2168, 2000
6. Pasceri V, Cheng JS, Willerson JT, Yeh ET, Chang J: Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 103: 2531-2534, 2001
7. Wang CH, Li SH, Weisel RD, Fedak PW, Dumont AS, Szmitko P, Li RK, Mickle DA, Verma S: C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 107: 1783-1790, 2003
8. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, Dhillon B, Weisel RD, Li RK, Mickle DA, Stewart DJ: A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 106: 913-919, 2002
9. Verma S, Badiwala MV, Weisel RD, Li SH, Wang CH, Fedak PW, Li RK, Mickle DA: C-reactive protein activates the nuclear factor-kappaB signal transduction pathway in saphenous vein endothelial cells: Implications for atherosclerosis and restenosis. J Thorac Cardiovasc Surg 126:1886-1891, 2003
10. Verma S, Kuliszewski MA, Li SH, Szmitko PE, Zucco L, Wang CH, Badiwala MV, Mickle DA, Weisel RD, Fedak PW, Stewart DJ, Kutryk MJ: C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: Further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 109: 2058-2067, 2004
11. Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, Davos CH, Cicoira M, Shamim W, Kemp M, Segal R, Osterziel KJ, Leyva F, Hetzer R, Ponikowski P, Coats AJ: Uric acid and survival in chronic heart failure: Validation and application in metabolic, functional, and hemodynamic staging. Circulation 107: 1991-1997, 2003
12. Saito M, Ishimitsu T, Minami J, Ono H, Ohrui M, Matsuoka H: Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors. Atherosclerosis 167: 73-79, 2003
13. Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD: Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 106: 221-226, 2002
14. Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, Pavitt DV, Reaveley DA, Schuler G, Coats AJ, Anker SD, Hambrecht R: Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure. Circulation 105: 2619-2624, 2002
15. Feig DI, Johnson RJ: Hyperuricemia in childhood essential hypertension. Hypertension 42: 247-252, 2003
16. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M: Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 41: 1183-1190, 2003
17. Ames BN, Cathcart R, Schwiers E, Hochstein P: Uric acid provides an antioxidant defence against oxidant and radical caused aging and cancer: A hypothesis. Proc Natl Acad Sci U S A 78: 6858-6862, 1981
18. Rao GN, Corson MA, Berk BC: Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet derived growth factor A-chain expression. J Biol Chem 266: 8604-8608, 1991
19. Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, Kang DH, Gordon KL, Watanabe S, Nakagawa T, Lan HY, Johnson RJ: Hyperuricemia induces a primary arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 282: F991-F997, 2002
20. Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, Wamsley A, Sheikh-Hamad D, Lan HY, Feng L, Johnson RJ: Uric acid stimulates MCP-1 production in vascular smooth muscle cells via MAPK and COX-2. Hypertension 41: 1287-1293, 2003
21. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ: Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38: 1101-1106, 2001
22. Kang DH, Nakagawa T, Feng L, Johnson RJ: A role for uric acid in renal progression. J Am Soc Nephrol 13: 2888-2897, 2002
23. Gimbrone MA, Cotran RS, Folkman J: Human vascular endothelial cells in culture. Growth and DNA synthesis. J Cell Biol 60: 673-684, 1974
24. Dubey RK, Gillespie DG, Mi Z, Jackson EK: Adenosine inhibits growth of human aortic smooth muscle cells via A2B receptors. Hypertension 31: 516-521, 1998
25. Calabro P, Willerson JT, Yeh ET: Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 108: 1930-1932, 2003
26. Kang DH, Han L, Ouyang X, Kahn AM, Kanellis J, Li P, Feng L, Nakagawa T, Watanabe S, Hosoyamada M, Endou H, Lipkowitz M, Abramson R, Mu W, Johnson RJ: Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. Am J Nephrol 25: 425-433, 2005
27. Pepys MB: C-reactive protein fifty years on. Lancet 21: 653-657, 1981
28. Yasojima K, Schwab C, McGeer EG, McGeer PL: Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 158: 1039-1051, 2001
29. Diehl EE, Haines GK 3rd, Radosevich JA, Potempa LA: Immunohistochemical localization of modified C-reactive protein antigen in normal vascular tissue. Am J Med Sci 319: 79-83, 2000
30. Nakahara C, Kanemoto K, Saito N, Oyake Y, Kamoda T, Nagata M, Matsui A: C-reactive protein frequently localizes in the kidney in glomerular diseases. Clin Nephrol 55: 365-370, 2001
31. Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H, Mazzali M, Johnson RJ: Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 40: 355-360, 2002
32. Mazzali M, Kim Y-G, Suga S, Gordon KL, Kang DH, Jefferson JA, Hughes J, Kivlighn SD, Lan HY, Johnson RJ: Hyperuricemia exacerbates chronic cyclosporine nephropathy. Transplantation 71: 900-905, 2001
33. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, Krotova K, Block ER, Prabhakar S, Johnson RJ: Hyperuricemia induces endothelial dysfunction. Kidney Int 67: 1739-1742, 2005
34. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A: Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101: 948-954, 2000
35. Wang Q, Zhu X, Xu Q, Ding X, Chen YE, Song Q: Effect of C-reactive protein on gene expression in vascular endothelial cells. Am J Physiol Heart Circ Physiol 288: H1539-H1545, 2005
36. van den Berg CW, Taylor KE, Lang D: C-reactive protein-induced in vitro vasorelaxation is an artefact caused by the presence of sodium azide in commercial preparations. Arterioscler Thromb Vasc Biol 24: e168-e171, 2004
37. Klein R, Klein BE, Cornoni JC, Maready J, Cassel JC, Tyroler HA: Serum uric acid. Its relationship to coronary heart disease risk factors and cardiovascular disease, Evans County, Georgia. Arch Intern Med 132: 401-410, 1973